Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy

NCT03278717 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT03278717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03278717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy
Lead sponsor
University College, London
Phase
Phase 3
Overall status
Unknown status
Start date
June 15, 2018
Completion date
December 31, 2023
Enrollment
330 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer